Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonardo Calza

Showing results (91-100 of 188) with videos related to

Pageof 19
Sort By:
International Journal of STD & AIDS|April 20, 2019
Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre studySebastiano Rizzardo, Massimiliano Lanzafame, Emanuela Lattuada, et al.
Journal of Medical Microbiology|April 10, 2026
Comparable efficacy of bictegravir/emtricitabine/tenofovir alafenamide and doravirine/lamivudine/tenofovir disoproxil fumarate in therapy-naive Human Immunodeficiency Virus adults with very high baseline viraemiaLeonardo Calza, Maddalena Giglia, Claudio Rigamonti, et al.
Antiviral Therapy|September 26, 2015
Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot studyLeonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, et al.
Recenti Progressi in Medicina|July 19, 2003
[Nosocomial methicillin-resistant staphylococci that remain sensitive to non-beta lactam antibiotics]Roberto Manfredi, Anna Nanetti, Samanta Morelli, et al.
Tuberculosis (Edinburgh, Scotland)|September 16, 2003
Role of Mycobacterium xenopi disease in patients with HIV infection at the time of highly active antiretroviral therapy (HAART). Comparison with the pre-Haart periodRoberto Manfredi, Anna Nanetti, Marina Tadolini, et al.
Scandinavian Journal of Infectious Diseases|April 2, 2011
Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patientsLeonardo Calza, Filippo Trapani, Sara Tedeschi, et al.
HIV Clinical Trials|October 9, 2004
A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infectionRoberto Manfredi, Anna Nanetti, Samanta Morelli, et al.
AIDS (London, England)|June 17, 2005
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemiaLeonardo Calza, Roberto Manfredi, Vincenzo Colangeli, et al.
The New Microbiologica|May 2, 2025
Decrease in drug-drug interactions between antiretroviral drugs and concomitant therapies in older people living with HIV-1 switching to bictegravir/emtricitabine/tenofovir alafenamideLeonardo Calza, Maddalena Giglia, Alberto Zuppiroli, et al.
Recenti Progressi in Medicina|February 18, 2003
[Reduction of antibiotic resistance of Enterococcus faecalis in infections of the genitourinary tract]Roberto Manfredi, Anna Nanetti, Roberta Valentini, et al.
Pageof 19

Showing results (91-100 of 188) with videos related to

Sort By:
Pageof 19
International Journal of STD & AIDS|April 20, 2019
Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre studySebastiano Rizzardo, Massimiliano Lanzafame, Emanuela Lattuada, et al.
Journal of Medical Microbiology|April 10, 2026
Comparable efficacy of bictegravir/emtricitabine/tenofovir alafenamide and doravirine/lamivudine/tenofovir disoproxil fumarate in therapy-naive Human Immunodeficiency Virus adults with very high baseline viraemiaLeonardo Calza, Maddalena Giglia, Claudio Rigamonti, et al.
Antiviral Therapy|September 26, 2015
Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot studyLeonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, et al.
Recenti Progressi in Medicina|July 19, 2003
[Nosocomial methicillin-resistant staphylococci that remain sensitive to non-beta lactam antibiotics]Roberto Manfredi, Anna Nanetti, Samanta Morelli, et al.
Tuberculosis (Edinburgh, Scotland)|September 16, 2003
Role of Mycobacterium xenopi disease in patients with HIV infection at the time of highly active antiretroviral therapy (HAART). Comparison with the pre-Haart periodRoberto Manfredi, Anna Nanetti, Marina Tadolini, et al.
Scandinavian Journal of Infectious Diseases|April 2, 2011
Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patientsLeonardo Calza, Filippo Trapani, Sara Tedeschi, et al.
HIV Clinical Trials|October 9, 2004
A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infectionRoberto Manfredi, Anna Nanetti, Samanta Morelli, et al.
AIDS (London, England)|June 17, 2005
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemiaLeonardo Calza, Roberto Manfredi, Vincenzo Colangeli, et al.
The New Microbiologica|May 2, 2025
Decrease in drug-drug interactions between antiretroviral drugs and concomitant therapies in older people living with HIV-1 switching to bictegravir/emtricitabine/tenofovir alafenamideLeonardo Calza, Maddalena Giglia, Alberto Zuppiroli, et al.
Recenti Progressi in Medicina|February 18, 2003
[Reduction of antibiotic resistance of Enterococcus faecalis in infections of the genitourinary tract]Roberto Manfredi, Anna Nanetti, Roberta Valentini, et al.
Pageof 19